179 related articles for article (PubMed ID: 22894669)
1. Glycans as targets for therapeutic antitumor antibodies.
Rabu C; McIntosh R; Jurasova Z; Durrant L
Future Oncol; 2012 Aug; 8(8):943-60. PubMed ID: 22894669
[TBL] [Abstract][Full Text] [Related]
2. Selection of GM2, fucosyl GM1, globo H and polysialic acid as targets on small cell lung cancers for antibody mediated immunotherapy.
Livingston PO; Hood C; Krug LM; Warren N; Kris MG; Brezicka T; Ragupathi G
Cancer Immunol Immunother; 2005 Oct; 54(10):1018-25. PubMed ID: 15926079
[TBL] [Abstract][Full Text] [Related]
3. [Monoclonal anti-idiotype antibodies in immunotherapy of ovarian carcinoma (MAb ACA125) and breast carcinoma (MAb ACA14C5)].
Wagner U; Köhler S; Prietl G; Giffels P; Schmidt-Nicolai S; Schlebusch H; Grünn U; Bender H; Biersack HJ; De Potter C; Krebs D; Wallwiener D
Zentralbl Gynakol; 1999; 121(4):190-5. PubMed ID: 10355096
[TBL] [Abstract][Full Text] [Related]
4. [Gangliosides as carbohydrate antigens associated with cancer and their possible use in tumor immunotherapy].
Horwacik I
Przegl Lek; 2004; 61 Suppl 2():14-9. PubMed ID: 15686040
[TBL] [Abstract][Full Text] [Related]
5. Lysis of human tumor cell lines by canine complement plus monoclonal antiganglioside antibodies or natural canine xenoantibodies.
Helfand SC; Hank JA; Gan J; Sondel PM
Cell Immunol; 1996 Jan; 167(1):99-107. PubMed ID: 8548851
[TBL] [Abstract][Full Text] [Related]
6. Controlled glycosylation of therapeutic antibodies in plants.
Tekoah Y; Ko K; Koprowski H; Harvey DJ; Wormald MR; Dwek RA; Rudd PM
Arch Biochem Biophys; 2004 Jun; 426(2):266-78. PubMed ID: 15158677
[TBL] [Abstract][Full Text] [Related]
7. Engineering anti-GD2 monoclonal antibodies for cancer immunotherapy.
Ahmed M; Cheung NK
FEBS Lett; 2014 Jan; 588(2):288-97. PubMed ID: 24295643
[TBL] [Abstract][Full Text] [Related]
8. Tumor-Associated Glycans as Targets for Immunotherapy: The Wistar Institute Experience/Legacy.
Thurin M
Monoclon Antib Immunodiagn Immunother; 2021 Jun; 40(3):89-100. PubMed ID: 34161162
[TBL] [Abstract][Full Text] [Related]
9. Antibodies against GD2 ganglioside can eradicate syngeneic cancer micrometastases.
Zhang H; Zhang S; Cheung NK; Ragupathi G; Livingston PO
Cancer Res; 1998 Jul; 58(13):2844-9. PubMed ID: 9661900
[TBL] [Abstract][Full Text] [Related]
10. Plant-derived anti-Lewis Y mAb exhibits biological activities for efficient immunotherapy against human cancer cells.
Brodzik R; Glogowska M; Bandurska K; Okulicz M; Deka D; Ko K; van der Linden J; Leusen JH; Pogrebnyak N; Golovkin M; Steplewski Z; Koprowski H
Proc Natl Acad Sci U S A; 2006 Jun; 103(23):8804-9. PubMed ID: 16720700
[TBL] [Abstract][Full Text] [Related]
11. Functional properties and effect on growth suppression of human neuroblastoma tumors by isotype switch variants of monoclonal antiganglioside GD2 antibody 14.18.
Mujoo K; Kipps TJ; Yang HM; Cheresh DA; Wargalla U; Sander DJ; Reisfeld RA
Cancer Res; 1989 Jun; 49(11):2857-61. PubMed ID: 2720646
[TBL] [Abstract][Full Text] [Related]
12. The GD2-specific 14G2a monoclonal antibody induces apoptosis and enhances cytotoxicity of chemotherapeutic drugs in IMR-32 human neuroblastoma cells.
Kowalczyk A; Gil M; Horwacik I; Odrowaz Z; Kozbor D; Rokita H
Cancer Lett; 2009 Aug; 281(2):171-82. PubMed ID: 19339105
[TBL] [Abstract][Full Text] [Related]
13. Enhanced immune recognition of cryptic glycan markers in human tumors.
Newsom-Davis TE; Wang D; Steinman L; Chen PF; Wang LX; Simon AK; Screaton GR
Cancer Res; 2009 Mar; 69(5):2018-25. PubMed ID: 19223535
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy of advanced ovarian carcinomas by activation of the idiotypic network.
Wagner UA; Oehr PF; Reinsberg J; Schmidt SC; Schlebusch HW; Schultes B; Werner A; Prietl G; Krebs D
Biotechnol Ther; 1992; 3(1-2):81-9. PubMed ID: 1305894
[TBL] [Abstract][Full Text] [Related]
15. Combination therapy with interleukin-2 and antitumor monoclonal antibodies.
Sondel PM; Hank JA
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S121-7. PubMed ID: 9457407
[TBL] [Abstract][Full Text] [Related]
16. Glycans in immune recognition and response.
Amon R; Reuven EM; Leviatan Ben-Arye S; Padler-Karavani V
Carbohydr Res; 2014 May; 389():115-22. PubMed ID: 24680512
[TBL] [Abstract][Full Text] [Related]
17. Immunocytochemical study on internalization of anti-carbohydrate monoclonal antibodies.
Kusano A; Ohta S; Shitara K; Hanai N
Anticancer Res; 1993; 13(6A):2207-12. PubMed ID: 8297135
[TBL] [Abstract][Full Text] [Related]
18. Combined therapeutic effect of a monoclonal anti-idiotype tumor vaccine against NeuGc-containing gangliosides with chemotherapy in a breast carcinoma model.
Fuentes D; Avellanet J; Garcia A; Iglesias N; Gabri MR; Alonso DF; Vazquez AM; Perez R; Montero E
Breast Cancer Res Treat; 2010 Apr; 120(2):379-89. PubMed ID: 19377876
[TBL] [Abstract][Full Text] [Related]
19. Targeted immunotherapy for high-risk neuroblastoma--the role of monoclonal antibodies.
Parsons K; Bernhardt B; Strickland B
Ann Pharmacother; 2013 Feb; 47(2):210-8. PubMed ID: 23386066
[TBL] [Abstract][Full Text] [Related]
20. Ganglioside antigens expressed by human cancer cells.
Ritter G; Livingston PO
Semin Cancer Biol; 1991 Dec; 2(6):401-9. PubMed ID: 1810468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
